<DOC>
	<DOCNO>NCT03054909</DOCNO>
	<brief_summary>This single center , randomize phase II study IL-15Rα-Fc super-agonist complex ( ALT-803 ) give maintenance therapy completion 1st line IV/IP chemotherapy treatment advance ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>QUILT-2.021 : Phase I IP Followed SQ ALT-803 Ovarian Cancer</brief_title>
	<detailed_description>In study patient receive four 8 week cycle ALT-803 consist 4 weekly dos follow 4 week rest ( treatment ) . As known intraperitoneal ( IP ) administration ( route drug administration frequently use gynecologic cancer ) ALT-803 compare subcutaneous ( SQ ) administration , rout administration test . The primary objective trial select one method delivery testing .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Diagnosis epithelial ovarian , fallopian tube primary peritoneal carcinoma , receive least 3 cycle first line IV/IP cisplatin paclitaxel chemotherapy stable disease well define measurable/evaluable tumor and/or CA125 level Able begin study therapy within 3 week ( +/ 1 week ) final IV/IP chemotherapy Functioning intraperitoneal catheter ≥ 18 year age GOG performance status ≤ 2 ( appendix II ) Adequate organ function within 14 day registration define : Hematology : hemoglobin &gt; 8 g/dl , platelet &gt; 50 x 109/L Creatinine : ≤ 2.0 mg/dL Hepatic : SGOT SGPT &lt; 3 x upper limit institutional normal ( ULN ) Ability prednisone immunosuppressive drug ( &lt; 1 mg/day ) least 3 day prior receive ALT803 Available archive tumor ( formalinfixed , paraffinembedded tissue block ) genomic proteomic analysis Voluntary write consent prior performance research related procedure Received investigational agent within 14 day start ALT803 Class II great New York Heart Association Functional Classification criterion ( appendix II ) serious cardiac arrhythmia likely increase risk cardiac complication cytokine therapy ( e.g . ventricular tachycardia , frequent ventricular ectopy , supraventricular tachyarrhythmia require chronic therapy ) Marked baseline prolongation QT/QTc interval ( e.g . demonstration QTc interval great 500 millisecond ) Uncontrolled bacterial , fungal viral infection include HIV1/2 active hepatitis C/B chronic asymptomatic viral hepatitis allow Active autoimmune disease require systemic immunosuppressive therapy History severe asthma currently chronic systemic medication ( mild asthma require inhaled steroid eligible )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>